Update from IMI PREFER: Patient preferences in benefitrisk assessments during the medical product lifecycle
|
|
- Doris Phelps
- 5 years ago
- Views:
Transcription
1 1 1 Update from IMI PREFER: Patient preferences in benefitrisk assessments during the medical product lifecycle Presenter: Chiara Whichello on behalf of the PREFER consortium June 5, 2018 The statements made in this presentation are those of the presenter and co-authors and not necessarily those of their employers or institutions, the view of IMI, the EU, or EFPIA.
2 2 2 Overview 1. What is PREFER and its goal? 2. What is patient preference information (PPI)? 3. How will PREFER achieve its goal? 4. Results from Work Package 2: Assessing patient preference elicitation and exploration methods
3 3 3 About the PREFER project The Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) is a five year project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.
4 4 4 PREFER 5-Year Public-Private Partnership ( ) 33 partners, 8 countries 10 Academic research institutions 4 Patient representatives 1 Health Technology Assessment body 2 SMEs (small and medium sized enterprises) 16 Pharmaceutical companies Additional Stakeholders Advisory Groups: Patients, HTA/Payers, Regulators Scientific Advisory Board / Extended Network
5 5 5 Goal of IMI PREFER Project To strengthen patient-centric decision making throughout the medical product life cycle by developing expert and evidence-based recommendations on how patient preferences should be assessed and inform decision making.
6 6 Three Types of Patient Preference Information Type Attributes Relative Importance Tradeoffs What it Measures What Matters How much it matters (relative to something else) What tradeoffs patients are willing to make between benefits, harms, and other aspects (e.g.. convenience of dosing) Adapted from RTI-HS
7 7 7 PREFER Stepwise Work Packages Work Package 2 Stakeholder Needs / Methods Review Determining stakeholder needs for patient preference use in MPLC Identifying and appraising methods for clinical case and simulation studies Methods: Literature reviews, Interviews, focus groups, (stakeholders and health preference experts) Work Package 3 Clinical case and simulation studies Designed to address issues / questions raised in needs assessment Academia-led studies Industry-led studies Simulations Work Package 4 Recommendations Document(s) Preference assessment and application to decisions throughout the lifecycle For health authorities, industry and payers/hta Work Package 1: Overall project management, including communication / dissemination
8 8 8 2 Results from WP2: Assessing patient preference elicitation and exploration methods
9 9 9 T2.4: Preference exploration methods
10 10 10 T2.4: Preference elicitation methods
11 11 11 T2.6: Q-Methodology Results Criteria to be included in AHP A typical survey can be conducted at relatively low costs Data can be collected during quick sessions with participants Low frequency of sessions required by patients Relatively quick delivery of preparation, data collection, and analysis A large number of attributes can be explored Suitable to study preferences in a small sample size A low cognitive load on patients Does not need an education tool or preparatory instructions in order to enhance participant comprehension Publically acknowledged by your organisation s guidelines as an acceptable method to study preferences New attributes can be added without making prior results invalid Can be used to collect data from more than one participant in a single session The analysis can calculate risk attitudes, like risk tolerance, and calculate how value functions bend due to the presence of uncertainty in the participant Explores the reasons behind a preference in detail Can estimate weights for attributes Estimates trade-offs that patients are willing to make among attributes Can quantify heterogeneity in preferences Establishes internal validity Establishes external validity Early development A (mechanism known) Early development B (mechanism not known) Late phase III Postmarketing
12 12 12 T2.6: Analytic Hierarchy Process (AHP) Results
13 13 13 T2.7: Identifying candidate methods Criteria (from Q- methodology) Identified in WP 2.6 Identified in WP 2.7 MPLC Stages AHP Results Method Assessment Weights Method Performance Publication Frequency Theory Concerns Identification of 12 candidate exploration and elicitation methodologies (suitable/likely to meet most decision makers needs) + Identification of 11 promising methods (identified potential theoretical or publication frequency issues of which decision-makers must be aware)
14 14 14 T2.7: Identifying candidate methods eg. Appraising threshold techniques * Informed exclusively by literature, and not expert interviews Red indicates that these methods would likely not suit most decision makers needs during this stage + + means 1.51, + means , - means , - - means 0
15 15 15 T2.7: Twelve most promising candidate PP methods Exploration methods Elicitation methods Group methods Individual methods Discrete choicebased Threshold techniques Focus groups Semistructured interviews In-depth interviews Discrete choice experiments / best-worst scaling 3 (Probabilistic) threshold technique Time trade-off Standard gamble Ratingrelated Rankingrelated Swing weighting Visual analogue scale Best-worst scaling 1 Best-worst scaling 2 Analytical hierarchy process
16 16 16 T2.7: Eleven potential candidate PP methods Exploration methods Elicitation methods Group methods Individual methods Discrete choice-based Threshold techniques Nominal group technique Public meetings Dyadic interviews Adaptive conjoint analysis Test trade-off Starting known efficacy Ratingrelated Rankingrelated Outcome prioritization tool Constant sum scaling Control preferences scale Q- methodology Qualitative discriminant process
17 17 17 Clinical Case and Simulation Studies Methodological questions identified during WP2 will be investigated using patient preference studies Studies to be conducted in at least three disease areas where patients and clinical research partners already provide expertise: Cancer Rheumatoid arthritis Neuromuscular disorders Partners from the pharmaceutical industry will provide additional patient preference studies to cover disease areas from the companies portfolio.
18 18 18 Scope of Recommendations Industry internal decisions Product strategy (e.g. TPP), stage gate decisions, B-R assessments Clinical trial design Endpoint selection, effect size, Regulatory benefit-risk assessments, Industry preparation, regulatory assessments, post-approval benefit-risk Health technology expert assessments Recommendations for individual products or classes of products Payer reimbursement decisions, Reimbursement for a specific product or classes of products Public agency decisions (e.g. public private partnerships, regulatory agencies)
19 19 19 In summary, PREFER Will establish recommendations for Industry, Regulatory Authorities, and HTA bodies on how and when to perform patient preference studies include patient preferences in decision-making Includes a diverse consortium that involves many stakeholder groups (including patients): both as partners and advisors Link to PREFER website:
20 20 20 Acknowledgements PREFER consortium PREFER partners Stakeholder advisory groups Scientific advisory board Extended stakeholders Contact information:
ITCC-P4 International Workshop
ITCC P4 GA No. 116064 ITCC-P4 International Workshop IMPROVING PEDIATRIC ONCOLOGY DRUG DEVELOPMENT THROUGH PRECLINICAL RESEARCH September 27 th and 28 th, 2018 // Amsterdam, NL By invitation The event
More informationIndustry Perspective on Patient Preference Information
Industry Perspective on Patient Preference Information FDA/CERSI PPI Workshop November 7, 2017 Bennett Levitan, MD-PhD Benefit-Risk Team Lead Department of Epidemiology Janssen Research & Development,
More informationRD-ACTION DISSEMINATION PLAN TABLE I - STAKEHOLDER ANALYSIS
RD-ACTION DISSEMINATION PLAN TABLE I - STAKEHOLDER ANALYSIS Stakeholder Group Interest in RD-Action Dissemination purpose Channels of Dissemination (WHO) (WHY) (WHY) (HOW) Partners of RD-Action & members
More information14 December :00 CET
Webinar IMI2 Call 13 Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches 14 December 2017 15:00 CET Agenda How to use
More informationDiscovery and validation of novel. Webinar IMI2 - Call 9 Joint influenza vaccine effectiveness studies
Discovery and validation of novel Webinar IMI2 - Call 9 Joint influenza vaccine effectiveness studies Dr. Angela Wittelsberger, IMI IMI webinar 29.04.2016 Today s webinar Will cover all aspects of the
More informationEMERALD: Improving diabetes outcomes for people with severe mental illness
EMERALD: Improving diabetes outcomes for people with severe mental illness Dr Sue Bellass Research Fellow Mental Health and Addiction Research Group University of York https://www.york.ac.uk/healthsciences/research/mental-health/
More informationReal world Outcomes across the AD spectrum for better care: Multi-modal data Access Platform
Real world Outcomes across the AD spectrum for better care: Multi-modal data Access Platform Catherine Reed, Lilly on behalf of ROADMAP consortium 3 rd Nordic conference on Real World Data, 28-29 November
More information2008 Public Status Report on the Implementation of the European Risk Management Strategy. Executive Summary
European Medicines Agency London, 17 March 2009 Doc. Ref. EMEA/43556/2009 2008 Status Report on the Implementation of the European Risk Management Strategy Executive Summary The European Risk Management
More informationFrom IMI to IMI2. Hugh Laverty Senior Scientific Project Manager
From IMI to IMI2 Hugh Laverty Senior Scientific Project Manager FitForHealth June 2014 Innovative Medicines Initiative: Joining forces in the healthcare sector The biggest public/private partnership in
More informationEUPATI beyond January 2017 Nicola Bedlington and the EUPATI Team
EUPATI beyond January 2017 Nicola Bedlington and the EUPATI Team The EUPATI journey so far what have we achieved after 5 years? A trusted and credible public-private partnership between patient organisations,
More informationThe Innovative Medicines Initiative: an engine for therapeutic innovation
The Innovative Medicines Initiative: an engine for therapeutic innovation Michel Goldman 26.11.2014 Brussels Bringing health-related life science and technology sectors into IMI2 The pillars of innovation
More informationDevelopment of novel inhaled antibiotic regimens in patients with cystic fibrosis (CF) and patients with non-cf bronchiectasis (BE)
Development of novel inhaled antibiotic regimens in patients with cystic fibrosis (CF) and patients with non-cf bronchiectasis (BE) Dr. Juliane Bernholz, Novartis (Coordinator) Dr. Andrea Appenzeller,
More informationUsing Health Economics to Inform the Development of Medical Devices. Matthew Allsop MATCH / BITECIC
Using Health Economics to Inform the Development of Medical Devices Matthew Allsop MATCH / BITECIC Overview Background to MATCH Overview of health economics in product development Concepts relating to
More informationPeer counselling A new element in the ET2020 toolbox
shutterstock Peer counselling A new element in the ET2020 toolbox Information Note. Main characteristics of the peer counselling tool Peer learning in the context of the education cooperation at EU level
More informationFuture of Diabetes Research in Europe JDRF Perspective
Future of Diabetes Research in Europe JDRF Perspective IMI-JDRF Diabetes Patient Meeting 20 May 2014 Brussels, Belgium Olivier ARNAUD, Pharm D JDRF European Research Director oarnaud@jdrf.org Future of
More informationPain and Palliative care in the European Commission s Framework Programmes. European Commission Research DG Dr. Elengo Manoussaki
Pain and Palliative care in the European Commission s Framework Programmes European Commission Research DG Dr. Elengo Manoussaki European Parliament resolution on combating cancer in the enlarged EU Calls
More informationImproving the care of patients suffering from acute or chronic pain
Improving the care of patients suffering from acute or chronic pain Petra Bloms-Funke, Hiltrud Liedgens, Keith Phillips, Jens Nagel 7 th December 2016 IMI webinar Pain Topics The continued high need for
More informationOverview of Engaging Young Men Project Follow-Up to Recommendations made in the Young Men and Suicide Project Report
Overview of Engaging Young Men Project Follow-Up to Recommendations made in the Young Men and Suicide Project Report Background Between March 2011 and October 2012, the Men s Health Forum in Ireland (MHFI)
More informationHow EHRA/ESC ventures into Horizon2020 funded trials. Nikos Dagres Chair of EHRA Scientific Initiatives Committee
How EHRA/ESC ventures into Horizon2020 funded trials Nikos Dagres Chair of EHRA Scientific Initiatives Committee EHRA involvement in Horizon2020 Importance Current status Obstacles Perspectives EHRA involvement
More informationALCOHOL, TOBACCO & OTHER DRUGS COUNCIL TAS INC.
ALCOHOL, TOBACCO & OTHER DRUGS COUNCIL TAS INC. STRATEGIC PLAN 2015 2018 ABOUT THE ATDC The Alcohol, Tobacco and other Drugs Council Tas Inc. (ATDC) is the peak body representing the interests of community
More informationEuropean Patients Academy on Therapeutic Innovation
European Patients Academy on Therapeutic Innovation http://www.patientsacademy.eu info@patientsacademy.eu The project is receiving support from the Innovative Medicines Initiative Joint Undertaking under
More informationMENTAL HEALTH SERVICE USER INVOLVEMENT Service User Involvement Project Worker The job description does not form part of the contract of employment
MENTAL HEALTH SERVICE USER INVOLVEMENT Service User Involvement Project Worker The job description does not form part of the contract of employment Salary: SCP 14-16 Hours: 37.5 hours per week Reports
More informationStated Preference Methods Research in Health Care Decision Making A Critical Review of Its Use in the European Regulatory Environment.
Stated Preference Methods Research in Health Care Decision Making A Critical Review of Its Use in the European Regulatory Environment. Kevin Marsh, Evidera Axel Mühlbacher, Hochschule Neubrandenburg Janine
More informationPriority Medicines for Europe and the World: Setting a public health based medicines development agenda
Priority Medicines for Europe and the World: Setting a public health based medicines development agenda Warren Kaplan, Veronika Wirtz (BU School of Public Health) Aukje Mantel, Pieter Stolk (UU) Béatrice
More informationBenefit-Risk Preference Methods: What Makes Rare Disease Unique?
15 September 2015 Benefit-Risk Preference Methods: What Makes Rare Disease Unique? Brett Hauber, PhD Senior Economist and Vice President Health Preference Assessment Annual Rare Disease Scientific Workshop
More informationPREVENTION FIRST : VACCINATION AT THE HEART OF PUBLIC HEALTH
PREVENTION FIRST : VACCINATION AT THE HEART OF PUBLIC HEALTH Vaccines Europe calls for EU leadership to develop a comprehensive EU vaccination strategy aimed to support Member States in implementing effective
More informationTowards tailored and targeted asthma self-management using mobile technologies
Towards tailored and targeted asthma self-management using mobile technologies Funded by the European Union Asthma: the problem Asthma is a lifelong chronic disease caused by inflammation of the airways,
More informationPandemic lessons learnt
Pandemic lessons learnt PCWP-HCPWG Joint meeting 28 February 2012 Presented by: Ragini Shivji, Monika Benstetter EMA An agency of the European Union Overview of presentation Background & Objective European
More informationMDIC Patient Centered Benefit-Risk Framework Report Public Release. May 13, 2015
1 MDIC Patient Centered Benefit-Risk Framework Report Public Release May 13, 2015 2 Introductory Remarks from MDIC Bill Murray, MDIC President and CEO MDIC Highlights 48 Members 5 Projects White House-FDA
More informationDetailing the Evolution of. Palliative Care: Creating a. Timeline
Detailing the Evolution of Palliative Care: Creating a Timeline Creating a Timeline: A Guide for Community Facilitators 1 Purpose The evolution of community based palliative care in First Nations communities
More informationWe are currently recruiting new members to advisory groups for the following research programmes:
Information for applicants to join NIHR as an advisory group member: HTA Programme Topic Identification, Development and Evaluation (TIDE) panel Chairs 1. Background information The goal of the National
More informationProgress from the Patient-Centered Outcomes Research Institute (PCORI)
Progress from the Patient-Centered Outcomes Research Institute (PCORI) Anne Beal, Chief Operating Officer of the Patient-Centered Outcomes Research Institute Sharon-Lise Normand, Vice Chair, Methodology
More informationBeyond vaccine introduction: Working together for sustainable, resilient immunization programs Manufacturer perspective
Beyond vaccine introduction: Working together for sustainable, resilient immunization programs Manufacturer perspective IAIM Regional Meeting for the Americas and Europe 1 February 2017 Anupama Tantri
More informationPROactive. Physical Activity as a Crucial Patient Reported Outcome in COPD. Thierry.troosters [AT] med.kuleuven.be Info [AT] proactivecopd.
PROactive Physical Activity as a Crucial Patient Reported Outcome in COPD Thierry.troosters [AT] med.kuleuven.be Info [AT] proactivecopd.be What patients need What Europe needs Chronic Obstructive Pulmonary
More informationIMI PROTECT Benefit-Risk Group. Massachusetts Institute of Technology Medicines and Healthcare products Regulatory Agency MerckSerono SA.
Pharmacoepidemiological Research on Outcomes of IMI PROTECT Benefit-Risk Group IMI PROTECT Benefit-Risk Group PATIENT AND PUBLIC INVOLVEMENT REPORT version 1.0 PATIENT AND PUBLIC INVOLVEMENT REPORT Recommendations
More informationBenefit-Risk modelling of pharmaceuticals:
Benefit-Risk modelling of pharmaceuticals: Where are we now? Professor Larry Phillips London School of Economics and Facilitations Limited EFSPI-FMS- DSBS Benefit- Risk Assessment Methodology Workshop
More informationAccelerating Patient-Centered Outcomes Research and Methodological Research
Accelerating Patient-Centered Outcomes Research and Methodological Research Jason Gerson, PhD CER Methods JSM 2016 July 31, 2016 In This Session PCORI Overview Methods Program Overview Methods Program
More informationPaolo Deluca, PhD Psychologist, Cooperativa di Studio e Ricerca Sociale Marcella
Alcohol and drug abuse prevention at the workplace in Italy: The Euridice model Paolo Deluca, PhD Psychologist, Cooperativa di Studio e Ricerca Sociale Marcella Background Euridice No drug addiction prevention
More informationCOMPUS Vol 2, Issue 8 December 2008
OPTIMAL THERAPY REPORT COMPUS Vol 2, Issue 8 December 2008 Gap Analysis and Key Messages for the Prescribing and Use of Insulin Analogues Supporting Informed Decisions À l appui des décisions éclairées
More informationThe EU strategy in Horizon2020 to fight poverty related diseases
Meeting on EDCTP2 French Ministry of Education, Science and Innovation, Paris 30 June 2017 The EU strategy in Horizon2020 to fight poverty related diseases Line Matthiessen Acting Director Health Directorate
More informationPROTECT Alcohol labelling policies to protect young people
PROTECT Alcohol labelling policies to protect young people EAHC 25 January 2010 Workshop on Best Practice Models 1 PROTECT: Alcohol labelling policies to protect young people Partners: CRIOC: coordinator
More informationThe Science of Eliciting Patient Preferences in Benefit-Risk!
The Science of Eliciting Patient Preferences in Benefit-Risk! Objective: Provide a common understanding of methods used to understand patient preferences for benefit expectations and risk tolerance, how
More informationSwiss National Strategy on Open Access
Swiss National Strategy on Open Access Preamble In a letter dated 4 December 2015, the State Secretariat for Education, Research and Innovation (hereinafter SERI) commissioned swissuniversities to elaborate,
More informationNICE decisions on health care provisions in England
NICE decisions on health care provisions in England Matt Stevenson, Professor of Health Technology Assessment (HTA), ScHARR, University of Sheffield, UK A quick introduction I am Technical Director of
More informationCFS MYPoW Chair Proposal on the HLPE work in 2018
Open Ended Working Group (OEWG) Multi-Year Programme of Work (MYPoW) Document No: CFS OEWG- MYPoW/2016/06/20/01 CFS OEWG-MYPoW Meeting # 02 Date: 20 June 2016 Time: 9.30-12.30 Location: Lebanon Room, FAO
More informationConcept note. Integrating World of Work response into National HIV/AIDS Programme in Mashreq Countries
Concept note Integrating World of Work response into National HIV/AIDS Programme in Mashreq Countries A Technical consultation meeting for National AIDS Program managers and ILO Constituents from Iraq,
More informationIntroducing NCCN Academy for Excellence & Leadership in Oncology April Program Overview
Introducing NCCN Academy for Excellence & Leadership in Oncology April 2009 Program Overview In 2009, NCCN will launch the NCCN Academy for Excellence & Leadership in Oncology, a series of oncology certificate
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/32777 holds various files of this Leiden University dissertation Author: Peay, Holly Landrum Title: Community-engaged approaches to explore research priorities
More informationEditorial. Facts. Dear colleagues and followers of the PERISCOPE Newsletters,
Editorial Dear colleagues and followers of the PERISCOPE Newsletters, We are very pleased to present the third issue of our e-newsletter with a special focus on clinical studies that have already been
More informationStudy protocol. Version 1 (06 April 2011) Ethics ref: R&D ref: UK CRC portfolio ID:
Identifying and prioritising important research questions for the treatment of eczema a collaborative partnership between patients, carers, clinicians and researchers Study protocol Version 1 (06 April
More informationEuropean map of investments in innovative digital solutions for AHA Early results
European map of investments in innovative digital solutions for AHA Early results Julien Venne Strategic Advisor, European Connected Health Alliance @ ECHAlliance / @JulienVenne THE BLUEPRINT STRATEGY
More informationNew Jersey Department of Human Services Quarterly Newsletter Division of Mental Health Services June 2006
Dear Mental Health Community, On February 10, 2006, the Division of Mental Health Services released a Wellness and Recovery Transformation Statement guiding the direction for future activities of New Jersey
More informationResults Based Advocacy to Increase Access Marie Stopes International
to Increase Access Marie Stopes International Women don t lease their bodies from the state or church, they own them. Founder, Tim Black (1937 2014) Almost all of the health services we provide throughout
More informationQuantitative benefit-risk assessment: An analytical framework for a shared understanding of the effects of medicines. Patrick Ryan 21 April 2010
Quantitative benefit-risk assessment: An analytical framework for a shared understanding of the effects of medicines Patrick Ryan 21 April 2010 Challenges in understanding the effects of medicines Benefit
More informationThe role of CAM in European health care
September 2012 European Policy Brief The Roadmap to Future CAM Research in Europe What is CAM? Complementary and Alternative Medicine (CAM) is the most commonly accepted term for the range of practices
More informationUnderstanding vaccine hesitancy in a post-factual era
Understanding vaccine hesitancy in a post-factual era Jonas Sivelä, Senior Researcher, PhD Infectious Disease Control and Vaccinations The Department of Health Security National Institute for Health and
More informationBDA IMPROVING ONCOLOGY DRUG DEVELOPMENT FOR CHILDREN AND ADOLESCENTS NOVEMBER 2013 WORKSHOP ADVANCE PROGRAMME
BDA WORKSHOP IMPROVING ONCOLOGY DRUG DEVELOPMENT FOR CHILDREN AND ADOLESCENTS 18-19 NOVEMBER 2013 PARIS, FRANCE BIOTHERAPY DEVELOPMENT ASSOCIATION encca European Network for Cancer Research in Children
More informationObesity Policy in the EU - evaluating the options. Cross-national findings
Obesity Policy in the EU - evaluating the options PorGrow project 2004-2006 Cross-national findings Erik Millstone University of Sussex e.p.millstone@sussex.ac.uk The full title was: Policy options for
More informationA Framework for Patient-Centered Outcomes Research
A Framework for Patient-Centered Outcomes Research David H. Hickam, MD, MPH Director of Research Methodology, PCORI Baltimore, MD August 9, 2016 Session Faculty Disclosures David H. Hickam, MD, MPH No
More informationAdvancing Use of Patient Preference Information as Scientific Evidence in Medical Product Evaluation Day 2
Advancing Use of Patient Preference Information as Scientific Evidence in Medical Product Evaluation Day 2 Theresa Mullin, PhD Director, Office of Strategic Programs FDA Center for Drug Evaluation and
More informationPaediatric Pulmonary Arterial Hypertension (PAH)
Paediatric Pulmonary Arterial Hypertension (PAH) Regulators perspective on a Global challenge EMA FDA HC paediatric PAH workshop 12 th June 2017 Cécile Ollivier European Medicines Agency Science and Innovation
More information6 Opportunities for Improving Pathways to Market: A Global Perspective on Dementia
6 Opportunities for Improving Pathways to Market: A Global Perspective on Dementia Raj Long Senior Regulatory Officer Bill & Melinda Gates Foundation Director Dementia Integrated Development UK HMG World
More informationGAVI, THE VACCINE ALLIANCE
#vaccineswork GAVI, THE VACCINE ALLIANCE Partnerships for Health Outcomes Susan Brown July, 2017, New York Gavi/2012/Doune Porter www.gavi.org 1 ABOUT GAVI Gavi s mission: to save children s lives and
More informationInvitation to Tender
Invitation to Tender Contact: Project: Jacob Diggle, Research and Evaluation Officer j.diggle@mind.org.uk Peer Support Programme Date: January 2015 Brief description: Mind has recently secured 3.2 million
More informationPosition Description: Senior Youth Worker (LGBTIQA+ Youth Portfolio)
Vision: Purpose: Values: A community where all young people are valued included and have every opportunity to thrive To enable young people experiencing serious disadvantage to access the resources and
More informationCOMMISSION OF THE EUROPEAN COMMUNITIES
COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 24.06.2009 (provisional version) COM(2009) 291/4 COMMUNICATION FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL
More informationStrategy for Personal and Public Involvement (PPI)
Strategy for Personal and Public Involvement (PPI) in Health and Social Care research HSC Research & Development Division Foreword I am delighted to present the second edition of the HSC R&D Division s
More informationONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE
CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES ONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE AT KANTAR HEALTH, ONCOLOGY
More informationHorizon Introduction. Alex Harris Medical Research Council
Horizon 2020 - Introduction Alex Harris Medical Research Council Agenda MRC and Horizon 2020 UK Success Rate (FP7 Health) What is Horizon 2020? The Horizon 2020 Health Challenge NCP support MRC and Horizon
More informationNew Horizons for Vaccine R&D&I in Europe
New Horizons for Vaccine R&D&I in Europe Health, Demographic Change and Wellbeing Ruxandra Draghia-Akli MD, PhD Directorate E - Health Research DG - Research & Innovation European Commission Why EU support
More informationBotswana Private Sector Health Assessment Scope of Work
Example of a Scope of Work (Botswana) Botswana Private Sector Health Assessment Scope of Work I. BACKGROUND The Republic of Botswana is a stable, democratic country in Southern Africa with an estimated
More informationCriteria for the evaluation of crime prevention practices
European Crime Prevention Network Criteria for the evaluation of crime prevention practices QUALIPREV short manual October 2016 RESEARCHER Anneleen Rummens PROMOTORS Prof. dr. Wim Hardyns Prof. dr. Freya
More informationSMART Communities Need A SMART Workforce Partners in SMART Education and Workforce Development & Training
SMART Communities Need A SMART Workforce Partners in SMART Education and Workforce Development & Training Who We Are What We Do SMART Community Exchange (SCE) founded in 2009, is an independent Public
More informationEstablishing LCA in the Healthcare Sector
Establishing LCA in the Healthcare Sector Nanja Hedal Kløverpris Abstract Novo Nordisk has used Life Cycle Assessment (LCA) for many years and a few years ago the company took a major step forward and
More informationIMI2 T1DM Call Topic Text: Translational approaches to disease modifying therapy of T1DM
IMI2 T1DM Call Topic Text: Translational approaches to disease modifying therapy of T1DM Dr Anke M Schulte, Head of Islet Biology Department Sanofi-Diabetes Frankfurt, Germany 11th of July, 2014 General
More informationNORDIC CONFERENCE ON RARE DISEASES
www.eurordis.org NORDIC CONFERENCE ON RARE DISEASES 31 May 2012, Reykjavik, Iceland www.eurordis.org RARE DISEASES IN EUROPE Terkel ANDERSEN President of EURORDIS European Organisation for Rare Diseases
More informationThe EU PIP - a step in Pediatric Drug Development. Thomas Severin Bonn,
The EU PIP - a step in Pediatric Drug Development Thomas Severin Bonn, 13.01.2009 Agenda Implications for Industry Company Preparation Time of PIP Submission Content of the PIP The PIP Process and first
More informationPatient and Public Involvement in JPND Research
Patient and Public Involvement in JPND Research A user-friendly guide for applicants to JPND Calls for proposals January 5 2015 Created in conjunction with DenDRoN, United Kingdom Purpose The purpose of
More informationInternational Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
Final Concept Paper E9(R1): Addendum to Statistical Principles for Clinical Trials on Choosing Appropriate Estimands and Defining Sensitivity Analyses in Clinical Trials dated 22 October 2014 Endorsed
More informationLessons learned along the path to qualification of an IBS outcome measure*
Lessons learned along the path to qualification of an IBS outcome measure* Stephen Joel Coons, PhD Patient-Reported Outcome (PRO) Consortium Critical Path Institute IMMPACT-XX WASHINGTON, DC July 14, 2017
More informationInformation Package. Director Quit Tasmania Permanent full time (76 hours per f/n, three year contract)
Information Package Director Quit Tasmania Permanent full time (76 hours per f/n, three year contract) We are seeking to employ a suitable individual to take on the challenging role of Director Quit Tasmania
More informationA Guide to End-point Assessment: Hair Professional
A Guide to End-point Assessment: Hair Professional Version 3 Contents 1. Introduction... 3 2. Purpose... 3 3. Entry requirements... 3 4. Duration... 4 5. Summary of assessment... 4 5.1 Assessment of the
More informationBriefing paper Horizon 2020 call SC1-PM Promoting mental health and well-being in the young
Briefing paper Horizon 2020 call SC1-PM-07-2017 Promoting mental health and well-being in the young Purpose of this paper To advise the AHSN and other interested parties of the proposal to form a partnership
More informationGender Aspects in R&I Horizon Stephanie Rammel Gender Expert in H2020 and ERA FFG - Austrian Research Promotion Agency
Gender Aspects in R&I Horizon 2020 Stephanie Rammel Gender Expert in H2020 and ERA FFG - Austrian Research Promotion Agency This presentation is about Horizon 2020: where are gender aspects relevant for
More informationThe basics a. Mission Statement (unchanged) eurordi s.org
The basics a. Mission Statement (unchanged) To build a strong pan-european community of patient organisations and people living with rare diseases, To be their voice at the European level And directly
More informationThe summit and its purpose
Sponsors: 1 The summit and its purpose The Translational Hearing Research Summit: Biological and Pharmacological Approaches was an international summit that gathered 159 delegates, from 14 countries to
More informationThe European Framework Program for Research & Innovation: Horizon 2020: Health, demographic change & wellbeing
The European Framework Program for Research & Innovation: Horizon 2020: Health, demographic change & wellbeing Sasha Hugentobler National Contact Point Health Euresearch Head Office phone +41 31 380 60
More informationPROPOSED WORK PROGRAMME FOR THE CLEARING-HOUSE MECHANISM IN SUPPORT OF THE STRATEGIC PLAN FOR BIODIVERSITY Note by the Executive Secretary
CBD Distr. GENERAL UNEP/CBD/COP/11/31 30 July 2012 ORIGINAL: ENGLISH CONFERENCE OF THE PARTIES TO THE CONVENTION ON BIOLOGICAL DIVERSITY Eleventh meeting Hyderabad, India, 8 19 October 2012 Item 3.2 of
More informationPOSTGRADUATE PROGRAMME SPECIFICATION
POSTGRADUATE PROGRAMME SPECIFICATION Programme Title: Awarding Body: Teaching Institution: Final Awards: Intermediate Awards: Mode of Study UCAS Codes: QAA Subject Benchmarks: JACS Code: Science Professional/Statutory
More informationPublic Health Masters (MPH) Competencies and Coursework by Major
I. Master of Science of Public Health A. Core Competencies B. Major Specific Competencies i. Professional Health Education ii. iii. iv. Family Activity Physical Activity Behavioral, Social, and Community
More informationAddendum to clinical guideline 131, Colorectal cancer
: National Institute for Health Care Excellence Final Addendum to clinical guideline 131, Colorectal cancer Clinical guideline addendum 131.1 Methods, evidence recommendations December 2014 Final version
More informationINSIGHTS INTO ADHD CARE IN GERMANY BASED ON SHI CLAIMS DATA 03. March Results of the CoCA Study (Horizon 2020)
03. March 2017 INSIGHTS INTO ADHD CARE IN GERMANY BASED ON SHI CLAIMS DATA Results of the CoCA Study (Horizon 2020) Who are we? HGC looks back on close to 30 years of experience in the health care sector
More informationThe HIV Prevention England programme: what s next? Cary James May 2016
The HIV Prevention England programme: what s next? Cary James May 2016 Summary Programme objectives Campaign evolution Sector development Structure and governance Support for HIV prevention system Communication
More informationTable Of Content. European Organisation for Rare Diseases... 2 Summary... 3 Coordinator, Leader contact and partners... 6 Outputs...
Table Of Content European Organisation for Rare Diseases... 2 Summary... 3 Coordinator, Leader contact and partners... 6 Outputs... 7 D04 - Electronic Newsletter (EN)... 7 D01 - Activity Report EURORDIS
More informationPHTHALATES STAKEHOLDER WORKSHOP SUMMARY REPORT
PHTHALATES STAKEHOLDER WORKSHOP SUMMARY REPORT March 26, 2014 Ottawa, Canada Contents Acronyms... 3 INTRODUCTION... 4 Overview Phthalate Substances Grouping and the Chemicals Management Plan... 5 The Proposed
More informationGENDER PLAN OF ACTION. Pocket Guide: Summary and Examples
2015 2020 GENDER PLAN OF ACTION Pocket Guide: Summary and Examples 2015 2020 Gender Plan of Action Pocket Guide: Summary and Examples At their twelfth meeting held in October 2014, the Parties to the
More informationJob Description. Inspire East Lancashire Integrated Substance use Service. Service User Involvement & Peer Mentor Co-ordinator
Job Description Service Job Title Base Hours Inspire East Lancashire Integrated Substance use Service Service User Involvement & Peer Mentor Co-ordinator Accrington 37.5 hours per week Salary Range 21,933.15-25,741.93
More informationTable Of Content. EURORDIS_FY Summary... 3 Coordinator, Leader contact and partners... 6 Outputs... 7
Table Of Content EURORDIS_FY2010... 2 Summary... 3 Coordinator, Leader contact and partners... 6 Outputs... 7 D04 - Electronic Newsletter and V.3 of EURORDIS website (EN)... 7 D01 - Activity Report OPERA
More information